3.5.6. hereditary kidney tumours. five eight percent rccs hereditary; date ten hereditary rcc syndromes associated specific germline mutations, rcc histology, comorbidities. hereditary rcc syndromes often suggested family history, age onset presence lesions typical respective syndromes. median age hereditary rcc 37 years; 70% hereditary rcc tumours found lowest decile (age 46 years younger) rcc tumours . hereditary kidney tumours found following entities: vhl syndrome; hereditary prcc; birt-hogg-dubé syndrome; fumarate hydratase-deficient rcc (fhd-rcc), previously called hereditary leiomyomatosis rcc (hlrcc); tuberous sclerosis; germline succinate dehydrogenase (sdh) mutation; non-polyposis colorectal cancer syndrome; hyperparathyroidism-jaw tumour syndrome; phosphatase tensin homolog (pten) hamartoma syndrome (phts); constitutional chromosome 3 translocation; familial non-syndromic ccrcc bap1-associated rcc . renal medullary carcinoma included association hereditary haemoglobinopathies [48-51]. patients hereditary kidney cancer syndromes may require repeated surgical intervention . hereditary rccs nephron-sparing approaches recommended. exceptions fhd-rcc sdh syndromes immediate surgical intervention recommended due aggressive nature tumours. hereditary syndromes vhl, surveillance recommended largest tumour reaches 3 cm diameter; limit number repeat interventions . active surveillance vhl, sdh fhd-rcc should, individual patients, follow size, growth rate location tumours, rather applying standardised follow-up interval. regular screening renal extra-renal lesions follow international guidelines syndromes . multidisciplinary co-ordinated care offered, appropriate . fhd-rcc, renal screening relatives shown benefit detecting early-stage rccs , hlrccs appearing unique molecular profiles. although hereditary, somatic fusion translocations tfe3 tfeb may affect 15% patients rcc younger 45 years 20-45% children young adults diagnosed rcc . phase ii trial demonstrated clinical activity oral hif-2α (hypoxia-inducible factor) inhibitor mk-6482 (belzutifan) vhl patients . additional information treatment vhl found section 7.4.4.